Gene therapy for genetic hearing loss is a nascent field with just a handful of studies published to date that demonstrate proof‐of‐concept recovery of auditory function (reviewed in Ahmed et al, ; Lustig & Akil, ). One challenge that faces the inner ear field, as well as the broader gene therapy field, is the need to deliver large gene sequences despite the limited genetic capacity (~4.5 kB) of delivery vehicles such as adeno‐associated viral vectors (AAV). In this issue, Al‐Moyed et al have overcome this conundrum by using two AAV vectors to deliver the coding sequence for otoferlin, which is ~6 kB. With dual‐AAV delivery of split otoferlin and a trans‐splicing approach, they demonstrate recombination of full‐length otoferlin in sensory h...
Because there are currently no biological treatments for deafness, we sought to advance gene therapy...
Otoferlin is a large multi-C2 domain protein indispensable for hearing and synaptic transmission in ...
Genetic hearing loss accounts for up to 50% of prelingual deafness worldwide, yet there are no biolo...
International audienceAutosomal recessive genetic forms (DFNB) account for most cases of profound co...
Normal hearing and synaptic transmission at afferent auditory inner hair cell (IHC) synapses require...
Adeno-associated virus (AAV) is a safe and effective vector for gene therapy for retinal disorders. ...
Efforts to develop gene therapies for hearing loss have been hampered by the lack of safe, efficient...
Gene therapy for genetic hearing loss is an emerging therapeutic modality for hearing restoration. H...
Virus-mediated transfer of genes encoding the mechanotransducer channel candidates TMC1 and TMC2 int...
Recent advances in human genomics led to the identification of numerous defective genes causing deaf...
Mammalian inner ear harbors diverse cell types that are essential for hearing and balance. Adenoviru...
Efforts to develop gene therapies for hearing loss have been hampered by the lack of safe, efficient...
Gene delivery is a key component for the treatment of genetic hearing loss. To date, a myriad of ade...
Hearing impairment is the most common sensory deficit in humans and degeneration of auditory hair ce...
Genetic loss of VGLUT3 in cochlear inner hair cells results in profound deafness. In this issue of N...
Because there are currently no biological treatments for deafness, we sought to advance gene therapy...
Otoferlin is a large multi-C2 domain protein indispensable for hearing and synaptic transmission in ...
Genetic hearing loss accounts for up to 50% of prelingual deafness worldwide, yet there are no biolo...
International audienceAutosomal recessive genetic forms (DFNB) account for most cases of profound co...
Normal hearing and synaptic transmission at afferent auditory inner hair cell (IHC) synapses require...
Adeno-associated virus (AAV) is a safe and effective vector for gene therapy for retinal disorders. ...
Efforts to develop gene therapies for hearing loss have been hampered by the lack of safe, efficient...
Gene therapy for genetic hearing loss is an emerging therapeutic modality for hearing restoration. H...
Virus-mediated transfer of genes encoding the mechanotransducer channel candidates TMC1 and TMC2 int...
Recent advances in human genomics led to the identification of numerous defective genes causing deaf...
Mammalian inner ear harbors diverse cell types that are essential for hearing and balance. Adenoviru...
Efforts to develop gene therapies for hearing loss have been hampered by the lack of safe, efficient...
Gene delivery is a key component for the treatment of genetic hearing loss. To date, a myriad of ade...
Hearing impairment is the most common sensory deficit in humans and degeneration of auditory hair ce...
Genetic loss of VGLUT3 in cochlear inner hair cells results in profound deafness. In this issue of N...
Because there are currently no biological treatments for deafness, we sought to advance gene therapy...
Otoferlin is a large multi-C2 domain protein indispensable for hearing and synaptic transmission in ...
Genetic hearing loss accounts for up to 50% of prelingual deafness worldwide, yet there are no biolo...